Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Syndax Pharmaceuticals (SNDX) Form 144 notice reports a proposed sale of 14,400 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $226,656. The securities were acquired by exercise of stock options on 08/18/2025 and payment was in cash the same day. The filing also discloses two recent Rule 10b5-1 sales by Dennis G. Podlesak in mid-August totaling 38,400 shares for gross proceeds of $570,928.80 ($298,408.32 and $272,520.48). The signee certifies no undisclosed material adverse information and notes any applicable 10b5-1 plan adoption where relevant.
Syndax Pharmaceuticals Schedule 13G/A shows that Point72-related entities and Steven A. Cohen report shared beneficial ownership of 2,307,824 shares of Syndax common stock, representing 2.7% of the class as of the close of business on June 30, 2025. The filing states Point72 Asset Management exercises shared voting and dispositive power over these shares on behalf of an investment fund it manages; Point72 Capital Advisors is the general partner and Mr. Cohen controls both entities. The filing clarifies the position is not intended to indicate an attempt to influence control of the issuer.
Form 144 notice for SNDX reports a proposed sale of 43,200 shares of common stock through Morgan Stanley Smith Barney LLC on 08/14/2025, with an aggregate market value of $581,040.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing lists 86,141,862 shares outstanding, and there are no reported sales by the same person in the prior three months.
The notice confirms the seller represents they have no undisclosed material adverse information and follows Rule 144 procedures for the proposed sale.
Schedule 13G/A filed for Syndax Pharmaceuticals, Inc. reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 5,581,828.06 shares of Syndax common stock, representing 6.5% of the class as reported for the event date 06/30/2025. The filing shows no sole voting or dispositive power and substantial shared voting power (5,581,718.06) and shared dispositive power (5,581,828.06). The cover exhibits include a joint filing agreement and identification of Goldman Sachs & Co. LLC as a subsidiary of GS Group. The registrants certify the securities are held in the ordinary course of business and not for the purpose of changing control.
Syndax Pharmaceuticals (SNDX) – Form 4 insider activity: Chief Financial Officer Keith A. Goldan purchased 1,226 common shares on 07/31/2025 under the company’s Employee Stock Purchase Plan (ESPP) at an average price of $8.43 per share. The transaction is coded “J,” confirming it is part of a tax-qualified plan rather than an open-market buy.
Following the purchase, Goldan’s direct ownership rises to 93,676 shares. No derivative securities were reported. The filing was submitted on 08/07/2025 and signed by attorney-in-fact Michael A. Metzger.
The acquisition is modest in dollar terms (≈$10 k) but represents incremental insider buying, which can be interpreted as a signal of management confidence. However, the size relative to Goldan’s total stake and SNDX’s share count suggests limited market impact.
Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.
While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.